NYSE:AGN - Allergan Stock Price, Price Target & More

Sign in or create an account to add this stock to your watchlist.
$153.66 -2.29 (-1.47 %)
(As of 05/24/2018 04:00 PM ET)
Previous Close$153.66
Today's Range$153.51 - $156.4497
52-Week Range$142.81 - $256.80
Volume1.74 million shs
Average Volume3.12 million shs
Market Capitalization$52.55 billion
P/E Ratio9.40
Dividend Yield1.86%
Beta1.17

About Allergan (NYSE:AGN)

Allergan logoAllergan plc, a specialty pharmaceutical company, develops, manufactures, markets, and distributes medical aesthetics, biosimilar, and over-the-counter pharmaceutical products worldwide. It operates through US Specialized Therapeutics, US General Medicine, and International segments. The company offers a portfolio of products that provide treatment for the central nervous system, gastroenterology, women's health and urology, ophthalmology, neurosciences, medical aesthetics, dermatology, plastic surgery, liver disease, inflammation, metabolic syndromes, and fibrosis, as well as Alzheimer's disease. It is also involved in developing ocular implants that reduce intraocular pressure associated with glaucoma; medical devices for the correction of prominent ears; and intranasal neurostimulation devices, as well as other dry eye products. In addition, the company distributes generic and branded pharmaceutical products primarily to independent and chain pharmacies, nursing homes, mail order pharmacies, hospitals, clinics, and physician offices. Further, it develops a portfolio of breast implants and tissue expanders; and RM-131 (relamorelin), a peptide ghrelin agonist for the treatment of diabetic gastroparesis. The company has licensing agreement with Assembly Biosciences, Inc.; Mimetogen Pharmaceuticals, Inc.; Almirall, S.A; Naurex, Inc.; and Merck & Co. The company was formerly known as Actavis plc and changed its name to Allergan plc in June 2015. Allergan plc was founded in 1983 and is headquartered in Dublin, Ireland.

Receive AGN News and Ratings via Email

Sign-up to receive the latest news and ratings for AGN and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryPharmaceuticals
SectorMedical
SymbolNYSE:AGN
CUSIP01849010
Phone862-261-7000

Debt

Debt-to-Equity Ratio0.36
Current Ratio1.10
Quick Ratio0.94

Price-To-Earnings

Trailing P/E Ratio9.40
Forward P/E Ratio9.59
P/E Growth1.11

Sales & Book Value

Annual Sales$15.94 billion
Price / Sales3.27
Cash Flow$39.8083 per share
Price / Cash3.86
Book Value$213.37 per share
Price / Book0.72

Profitability

EPS (Most Recent Fiscal Year)$16.35
Net Income$-4,125,500,000.00
Net Margins-11.94%
Return on Equity8.53%
Return on Assets5.00%

Miscellaneous

Employees17,800
Outstanding Shares339,060,000

Allergan (NYSE:AGN) Frequently Asked Questions

What is Allergan's stock symbol?

Allergan trades on the New York Stock Exchange (NYSE) under the ticker symbol "AGN."

How often does Allergan pay dividends? What is the dividend yield for Allergan?

Allergan declared a quarterly dividend on Thursday, May 3rd. Stockholders of record on Friday, May 18th will be given a dividend of $0.72 per share on Friday, June 15th. This represents a $2.88 dividend on an annualized basis and a dividend yield of 1.87%. The ex-dividend date is Thursday, May 17th. View Allergan's Dividend History.

How will Allergan's stock buyback program work?

Allergan announced that its Board of Directors has approved a stock repurchase plan on Tuesday, September 26th 2017, which allows the company to buyback $2,000,000,000.00 in shares, according to EventVestor. This buyback authorization allows the company to purchase up to 2.8% of its shares through open market purchases. Shares buyback plans are generally an indication that the company's leadership believes its stock is undervalued.

How were Allergan's earnings last quarter?

Allergan (NYSE:AGN) announced its quarterly earnings results on Monday, April, 30th. The company reported $3.74 earnings per share for the quarter, topping the Zacks' consensus estimate of $3.36 by $0.38. The firm earned $3.67 billion during the quarter, compared to analyst estimates of $3.59 billion. Allergan had a positive return on equity of 8.53% and a negative net margin of 11.94%. Allergan's revenue was up 2.8% compared to the same quarter last year. During the same period last year, the business posted $3.35 earnings per share. View Allergan's Earnings History.

When is Allergan's next earnings date?

Allergan is scheduled to release their next quarterly earnings announcement on Thursday, August, 2nd 2018. View Earnings Estimates for Allergan.

What guidance has Allergan issued on next quarter's earnings?

Allergan updated its FY18 earnings guidance on Monday, April, 30th. The company provided earnings per share guidance of $15.65-16.25 for the period, compared to the Thomson Reuters consensus earnings per share estimate of $15.66. The company issued revenue guidance of $15.15-15.35 billion, compared to the consensus revenue estimate of $15.24 billion.Allergan also updated its Q2 guidance to $4.00-4.20 EPS.

What price target have analysts set for AGN?

21 brokers have issued 1-year target prices for Allergan's stock. Their predictions range from $150.00 to $265.00. On average, they anticipate Allergan's stock price to reach $214.1616 in the next year. View Analyst Ratings for Allergan.

What are Wall Street analysts saying about Allergan stock?

Here are some recent quotes from research analysts about Allergan stock:
  • 1. Mizuho analysts commented, "We Look for Long Term Outlook Color on the Call Rating Neutral Previous Rating No Change Price (4/27) $162.04 Price Target $185.00 Previous Price Target No Change 1Q:18 beat and 2Q:18 guidance above consensus: AGN reported $3.67B in revs and non-GAAP EPS of $3.74 vs. $3.60B and $3.36 FactSet consensus. The company had guided 1Q:18 to $3.5B-$3.6B in revs and EPS of $3.20- $3.40, and outperformed these metrics handily. The 1Q:18 beat was driven by lower OpEx and higher international sales. Allergan raised 2018 revenue guidance to $15.150B-$15.350B from $15.0B-$15.3B due to the prolonged durability of Restasis (already expected, in our view) and correspondingly raised its non-GAAP EPS range to $15.65-$16.25 from $15.25-$16.00 vs. FactSet consensus of $15.24B and $15.67, respectively, which we attribute in part to reduced share count. Allergan also introduced 2Q:18 guidance of $3.85B-$4.00B and $4.00-$4.20 non-GAAP EPS vs. $3.86B and." (4/30/2018)
  • 2. Cantor Fitzgerald analysts commented, "This morning AGN reported a high quality 1Q18 EPS beat and raised its 2018 EPS guidance. This is clearly good news for the company, but we would note that a beat and raise was widely anticipated by the Street since AGN’s setup looked conservative heading into the year. Furthermore, if Restasis generics do not enter the market in 2018, we could see AGN continuing to beat its financial guidance throughout the year." (4/27/2018)
  • 3. According to Zacks Investment Research, "Allergan’s products like Botox and Linzess and new products such as Viberzi, Namzaric and Vraylar support sales. It also boasts a strong branded pipeline. Biosimilars also represent significant opportunity. However, while we remain optimistic about the company’s growth prospects, it is facing potential loss of exclusivity for many products in 2018 including Namenda XR and Restasis. In October 2017, a Texas federal district court invalidated four of the six patents covering Restasis, potentially opening doors for early generic competition. Though Restasis patents are scheduled to expire in August 2024, a generic version may be launched as early as mid-2018. Also, new competition for key growth drivers, Restasis and Linzess, is an investor concern. Allergan’s shares underperformed the industry in the past six months. " (1/2/2018)

Who are some of Allergan's key competitors?

Who are Allergan's key executives?

Allergan's management team includes the folowing people:
  • Mr. Brenton L. Saunders, Chairman, Pres & CEO (Age 48)
  • Mr. William Meury, Exec. VP & Chief Commercial Officer (Age 50)
  • Mr. Matthew M. Walsh, Exec. VP & CFO (Age 51)
  • Mr. Wayne R. Swanton, Exec. VP of Global Operations (Age 50)
  • Mr. James C. D'Arecca, Chief Accounting Officer (Age 47)

Has Allergan been receiving favorable news coverage?

Press coverage about AGN stock has trended somewhat positive on Thursday, Accern reports. Accern identifies negative and positive media coverage by reviewing more than twenty million blog and news sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Allergan earned a media sentiment score of 0.07 on Accern's scale. They also gave news stories about the company an impact score of 47.21 out of 100, indicating that recent media coverage is somewhat unlikely to have an impact on the stock's share price in the next few days.

Who are Allergan's major shareholders?

Allergan's stock is owned by many different of institutional and retail investors. Top institutional shareholders include BlackRock Inc. (6.06%), Edgewood Management LLC (1.65%), Franklin Resources Inc. (1.59%), The Manufacturers Life Insurance Company (1.25%), Northern Trust Corp (1.21%) and Epoch Investment Partners Inc. (0.55%). Company insiders that own Allergan stock include Brent L Saunders, Chris W Bodine, Christopher J Coughlin, Joseph H Boccuzi, Maria Teresa Hilado, Matthew M Walsh, Nesli Basgoz, Paul Bisaro and William Meury. View Institutional Ownership Trends for Allergan.

Which institutional investors are selling Allergan stock?

AGN stock was sold by a variety of institutional investors in the last quarter, including Amundi Pioneer Asset Management Inc., Prudential Financial Inc., Levin Capital Strategies L.P., Neuberger Berman Group LLC, BlackRock Inc., Epoch Investment Partners Inc., TCW Group Inc. and Swiss National Bank. View Insider Buying and Selling for Allergan.

Which institutional investors are buying Allergan stock?

AGN stock was purchased by a variety of institutional investors in the last quarter, including Summit Trail Advisors LLC, Edgewood Management LLC, Toronto Dominion Bank, Ceredex Value Advisors LLC, Point72 Asset Management L.P., Canyon Capital Advisors LLC, Wells Fargo & Company MN and Morningstar Investment Services LLC. Company insiders that have bought Allergan stock in the last two years include Brent L Saunders, Chris W Bodine, Christopher J Coughlin, Joseph H Boccuzi, Maria Teresa Hilado and Matthew M Walsh. View Insider Buying and Selling for Allergan.

How do I buy shares of Allergan?

Shares of AGN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Allergan's stock price today?

One share of AGN stock can currently be purchased for approximately $153.66.

How big of a company is Allergan?

Allergan has a market capitalization of $52.55 billion and generates $15.94 billion in revenue each year. The company earns $-4,125,500,000.00 in net income (profit) each year or $16.35 on an earnings per share basis. Allergan employs 17,800 workers across the globe.

How can I contact Allergan?

Allergan's mailing address is CLONSHAUGH BUSINESS AND TECHNOLOGY PARK COOLOCK, DUBLIN L2, D17 E400. The company can be reached via phone at 862-261-7000 or via email at [email protected]


MarketBeat Community Rating for Allergan (AGN)

Community Ranking:  3.4 out of 5 (star star star)
Outperform Votes:  1,023 (Vote Outperform)
Underperform Votes:  468 (Vote Underperform)
Total Votes:  1,491
MarketBeat's community ratings are surveys of what our community members think about Allergan and other stocks. Vote "Outperform" if you believe AGN will outperform the S&P 500 over the long term. Vote "Underperform" if you believe AGN will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Allergan (NYSE:AGN) Price Target and Consensus Rating

  (How are Consensus Ratings Calculated?)
21 Wall Street analysts have issued ratings and price targets for Allergan in the last 12 months. Their average twelve-month price target is $214.1616, suggesting that the stock has a possible upside of 39.37%. The high price target for AGN is $265.00 and the low price target for AGN is $150.00. There are currently 6 hold ratings and 15 buy ratings for the stock, resulting in a consensus rating of "Buy."
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyBuy
Consensus Rating Score: 2.712.682.702.63
Ratings Breakdown: 0 Sell Rating(s)
6 Hold Rating(s)
15 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
7 Hold Rating(s)
15 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
6 Hold Rating(s)
14 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
7 Hold Rating(s)
12 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $214.1616$220.1535$225.53$245.5882
Price Target Upside: 39.37% upside37.69% upside41.49% upside38.57% upside

Allergan (NYSE:AGN) Consensus Price Target History

Price Target History for Allergan (NYSE:AGN)

Allergan (NYSE:AGN) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
5/17/2018Wells Fargo & CoReiterated RatingBuyLowView Rating Details
5/7/2018Cantor FitzgeraldReiterated RatingHold$180.00LowView Rating Details
5/3/2018Credit Suisse GroupLower Price TargetOutperform ➝ Outperform$215.00 ➝ $213.00MediumView Rating Details
5/1/2018Bank of AmericaLower Price TargetBuy ➝ Buy$213.00 ➝ $209.00LowView Rating Details
5/1/2018MizuhoLower Price TargetNeutral$150.00MediumView Rating Details
5/1/2018Deutsche BankSet Price TargetBuy$210.00MediumView Rating Details
4/24/2018CitigroupReiterated RatingBuy ➝ Buy$220.00 ➝ $200.00MediumView Rating Details
4/23/2018Evercore ISIInitiated CoverageOutperformLowView Rating Details
4/17/2018Stifel NicolausInitiated CoverageHold ➝ Hold$192.00LowView Rating Details
4/16/2018CowenSet Price TargetBuy$255.00LowView Rating Details
3/26/2018Leerink SwannReiterated RatingOutperformHighView Rating Details
3/15/2018JPMorgan Chase & Co.Set Price TargetBuy$265.00LowView Rating Details
3/14/2018Royal Bank of CanadaReiterated RatingBuy$213.00LowView Rating Details
3/1/2018Morgan StanleyLower Price TargetOverweight ➝ Overweight$200.00 ➝ $181.00HighView Rating Details
2/23/2018SunTrust BanksInitiated CoverageBuy ➝ Buy$200.00LowView Rating Details
1/29/2018BarclaysUpgradeEqual Weight ➝ Overweight$220.00 ➝ $230.00LowView Rating Details
1/10/2018UBSSet Price TargetBuy$250.00MediumView Rating Details
12/7/2017ArgusDowngradeBuy ➝ Hold$256.80 ➝ $160.07LowView Rating Details
10/18/2017Edward JonesReiterated RatingBuy ➝ HoldN/AView Rating Details
10/18/2017Sanford C. BernsteinSet Price TargetBuy$296.00 ➝ $252.00N/AView Rating Details
10/13/2017Piper Jaffray CompaniesSet Price TargetHold$227.00N/AView Rating Details
5/10/2017Goldman Sachs GroupDowngradeBuy ➝ Neutral$262.00HighView Rating Details
11/21/2016William BlairReiterated RatingMarket PerformN/AView Rating Details
(Data available from 5/24/2016 forward)

Earnings

Allergan (NYSE:AGN) Earnings History and Estimates Chart

Earnings by Quarter for Allergan (NYSE:AGN)

Allergan (NYSE:AGN) Earnings Estimates

2018 EPS Consensus Estimate: $15.56
2019 EPS Consensus Estimate: $16.13
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20183$3.37$3.39$3.38
Q2 20184$3.17$4.24$3.86
Q3 20184$3.65$4.06$3.87
Q4 20184$4.16$4.95$4.45
Q1 20191$3.73$3.73$3.73
Q2 20191$4.01$4.01$4.01
Q3 20191$4.10$4.10$4.10
Q4 20191$4.29$4.29$4.29

Allergan (NYSE AGN) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
8/1/2018$4.03N/AView Earnings Details
4/30/2018Q1 2018$3.36$3.74$3.5945 billion$3.6721 billionViewListenView Earnings Details
2/6/2018Q4 2017$4.74$4.86$4.2813 billion$4.3261 billionViewListenView Earnings Details
11/1/2017Q3 2017$4.06$4.15$4.0377 billion$4.0340 billionViewN/AView Earnings Details
8/3/2017Q2 2017$3.95$4.02$3.9461 billion$4.0074 billionViewListenView Earnings Details
5/9/2017Q1 2017$3.32$3.35$3.5325 billion$3.5730 billionViewListenView Earnings Details
2/8/2017Q416$3.76$3.90$3.77 billion$3.86 billionViewListenView Earnings Details
11/2/2016Q316$3.57$3.32$3.73 billion$3.62 billionViewListenView Earnings Details
8/8/2016Q216$3.34$3.35$4.10 billion$3.68 billionViewListenView Earnings Details
5/10/2016Q116$3.03$3.04$3.97 billion$3.80 billionViewListenView Earnings Details
2/22/2016Q415$3.36$3.41$4.20 billion$4.20 billionViewListenView Earnings Details
11/4/2015Q315$3.20$3.48$5.71 billion$4.10 billionViewN/AView Earnings Details
8/6/2015Q215$4.41$4.41$5.71 billion$5.76 billionViewN/AView Earnings Details
5/11/2015Q115$3.84$4.30$4.04 billion$4.23 billionViewListenView Earnings Details
2/18/2015Q414$3.67$3.91$3.84 billion$4.01 billionViewN/AView Earnings Details
11/5/2014Q414$1.83$2.17$1.9018 billion$1.9105 billionViewN/AView Earnings Details
11/5/2014Q314$3.10$3.19$3.63 billion$3.68 billionViewN/AView Earnings Details
8/5/2014Q314$1.76$1.78$1.78 billion$1.79 billionViewListenView Earnings Details
8/5/2014Q214$3.36$3.42$2.55 billion$2.67 billionViewN/AView Earnings Details
7/21/2014Q214$1.44$1.51$1.77 billion$1.83 billionViewN/AView Earnings Details
4/30/2014Q114$1.13$1.18$1.60 billion$1.6460 billionViewN/AView Earnings Details
4/30/2014Q114$3.23$3.49$2.59 billion$2.66 billionViewListenView Earnings Details
2/20/2014Q413$3.05$3.17$2.68 billion$2.78 billionViewListenView Earnings Details
2/4/2014Q413$1.34$1.12$1.65 million$1.66 millionViewN/AView Earnings Details
10/29/2013Q313$1.20$1.23$1.53 billion$1.23 billionViewListenView Earnings Details
10/29/2013Q313$2.09$2.09$2.04 billion$2.01 billionViewListenView Earnings Details
7/31/2013Q2 2013$1.20$1.22$1.56 billion$1.5977 billionViewN/AView Earnings Details
7/25/2013Q2 2013$2.00$2.01$1.9857 billion$1.9898 billionViewListenView Earnings Details
5/2/2013Q1 2013$1.86$1.99$1.97 billion$1.90 billionViewListenView Earnings Details
5/1/2013Q1 2013$0.96$0.98$1.44 billion$1.46 billionViewN/AView Earnings Details
2/19/2013Q4 2012$1.53$1.59$1.74 million$1.75 billionViewListenView Earnings Details
2/5/2013Q4 2012$1.20$1.15$1.51 million$1.48 millionViewN/AView Earnings Details
10/30/2012Q312$1.04$1.06$1.43 billion$1.39 billionViewN/AView Earnings Details
8/1/2012$1.06$1.07ViewN/AView Earnings Details
5/2/2012$0.87$0.86ViewN/AView Earnings Details
2/14/2012Q4 2011$1.75$1.77ViewN/AView Earnings Details
2/2/2012$1.00$1.00ViewN/AView Earnings Details
10/26/2011$0.90$0.92ViewN/AView Earnings Details
8/3/2011$0.95$0.96ViewN/AView Earnings Details
7/26/2011Q2 2011$1.00$1.01ViewN/AView Earnings Details
5/4/2011$0.74$0.77ViewN/AView Earnings Details
2/15/2011Q4 2010$0.93$0.93ViewN/AView Earnings Details
2/2/2011$0.89$0.88ViewN/AView Earnings Details
11/4/2010Q3 2010$0.84$0.85ViewN/AView Earnings Details
8/5/2010Q2 2010$0.81$0.83ViewN/AView Earnings Details
5/10/2010Q1 2010$0.74$0.63ViewN/AView Earnings Details
2/23/2010Q4 2009$0.72$0.85ViewN/AView Earnings Details
11/4/2009Q3 2009$0.65$0.66ViewN/AView Earnings Details
7/29/2009Q2 2009$0.57$0.61ViewN/AView Earnings Details
4/30/2009Q1 2009$0.49$0.58ViewN/AView Earnings Details
2/19/2009Q4 2008$0.50$0.53ViewN/AView Earnings Details
10/29/2008Q3 2008$0.46$0.48ViewN/AView Earnings Details
8/6/2008Q2 2008$0.48$0.48ViewN/AView Earnings Details
5/1/2008Q1 2008$0.51$0.55ViewN/AView Earnings Details
2/20/2008Q4 2007$0.31$0.35ViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Dividends

Allergan (NYSE:AGN) Dividend Information

Allergan pays an annual dividend of $2.88 per share, with a dividend yield of 1.87%. AGN's next quarterly dividend payment will be made on Friday, June 15. Allergan pays out 17.61% of its earnings out as a dividend.
Next Dividend:6/15/2018
Annual Dividend:$2.88
Dividend Yield:1.87%
Dividend Growth:141.00% (3 Year Average)
Payout Ratio(s):17.61% (Trailing 12 Months of Earnings)
17.97% (Based on This Year's Estimates)
17.22% (Based on Next Year's Estimates)
7.23% (Based on Cash Flow)
Frequency:Quarterly Dividend
Dividend Payments by Quarter for Allergan (NYSE:AGN)

Allergan (NYSE:AGN) Dividend History by Quarter

AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
5/3/2018quarterly$0.721.95%5/17/20185/18/20186/15/2018
2/9/2018quarterly$0.721.71%2/27/20182/28/20183/28/2018
10/27/2017quarterly$0.701.58%11/16/201711/17/201712/15/2017
8/2/2017Quarterly$0.701.12%8/16/20178/18/20179/15/2017
5/5/2017quarterly$0.700.01%5/16/20175/18/20176/15/2017
11/2/2016quarterly$0.702/24/20172/28/20173/28/2017
2/4/2015quarterly$0.050.09%2/5/20152/9/20153/20/2015
10/27/2014quarterly$0.0511/20/201412/11/2014
7/28/2014quarterly$0.050.12%8/13/20148/15/20149/5/2014
5/7/2014quarterly$0.050.12%5/21/20145/23/20146/13/2014
2/5/2014quarterly$0.050.17%2/26/20142/28/20143/21/2014
10/30/2013quarterly$0.050.22%11/18/201311/20/201312/11/2013
7/31/2013quarterly$0.050.22%8/20/20138/22/20139/12/2013
5/2/2013quarterly$0.050.2%5/21/20135/23/20136/13/2013
2/6/2013quarterly$0.050.18%2/26/20132/28/20133/21/2013
(Data available from 1/1/2013 forward)

Insider Trades

Allergan (NYSE AGN) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 0.36%
Institutional Ownership Percentage: 79.57%
Insider Trading History for Allergan (NYSE:AGN)
Institutional Ownership by Quarter for Allergan (NYSE:AGN)

Allergan (NYSE AGN) Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
5/17/2018William MeuryEVPSell24,425$154.59$3,775,860.75View SEC Filing  
3/15/2018Maria Teresa HiladoInsiderBuy895$167.39$149,814.05View SEC Filing  
3/8/2018Brent L. SaundersCEOBuy3,300$152.53$503,349.00View SEC Filing  
3/8/2018Matthew M. WalshCFOBuy1,000$153.96$153,960.00View SEC Filing  
3/5/2018Joseph H. BoccuziDirectorBuy900$143.42$129,078.00View SEC Filing  
2/21/2018Matthew M WalshCFOBuy2,000$160.94$321,880.00View SEC Filing  
2/14/2018William MeuryInsiderSell58,879$160.62$9,457,144.98View SEC Filing  
12/7/2017Chris W. BodineDirectorBuy3,030$164.77$499,253.10View SEC Filing  
12/6/2017Brent L. SaundersChairmanBuy4,600$164.74$757,804.00View SEC Filing  
12/5/2017Christopher J. CoughlinDirectorBuy10,000$163.30$1,633,000.00View SEC Filing  
12/1/2017William MeuryInsiderSell11,807$173.89$2,053,119.23View SEC Filing  
5/18/2017Nesli BasgozDirectorSell1,889$220.45$416,430.05View SEC Filing  
3/2/2017Paul BisaroDirectorSell70,000$246.68$17,267,600.00274,226View SEC Filing  
12/8/2016Nesli BasgozDirectorSell500$188.72$94,360.00View SEC Filing  
11/21/2016Brent L. SaundersCEOBuy5,250$189.13$992,932.50View SEC Filing  
11/11/2016Maria Teresa HiladoCFOBuy1,422$210.64$299,530.0812,659View SEC Filing  
6/2/2016Maria Teresa HiladoCFOBuy661$241.57$159,677.7711,957View SEC Filing  
5/11/2016Nesli BasgozDirectorSell459$225.10$103,320.905,242View SEC Filing  
12/7/2015Nesli BasgozDirectorSell2,300$312.96$719,808.004,062View SEC Filing  
8/24/2015Paul BisaroChairmanBuy1,000$297.42$297,420.00421,755View SEC Filing  
8/21/2015Brent L SaundersCEOBuy1,000$301.94$301,940.00132,862View SEC Filing  
6/9/2015Nesli BasgozDirectorSell2,200$297.89$655,358.00View SEC Filing  
11/26/2014William MeuryInsiderSell4,550$269.14$1,224,587.00View SEC Filing  
9/8/2014Albert Paonessa IIIInsiderSell6,642$230.49$1,530,914.58View SEC Filing  
4/22/2014Scott ShermanEVPSell14,500$155.82$2,259,390.008,223View SEC Filing  
2/21/2014Louis Lavigne, Jr.DirectorSell5,400$125.79$679,266.0012,723View SEC Filing  
2/19/2014Dawn HudsonDirectorSell4,200$126.35$530,670.0011,600View SEC Filing  
2/19/2014Jeffrey EdwardsCFOSell38,900$126.39$4,916,571.0016,591View SEC Filing  
2/19/2014Raymond DiradoorianEVPSell23,000$126.66$2,913,180.006,401View SEC Filing  
2/18/2014Scott ShermanEVPSell5,001$125.74$628,825.748,220View SEC Filing  
1/14/2014Scott WhitcupVPSell42,000$117.80$4,947,600.0017,327View SEC Filing  
12/27/2013Julian GangolliVPSell52,500$110.05$5,777,625.00View SEC Filing  
12/20/2013Scott WhitcupVPSell33,000$108.80$3,590,400.0017,327View SEC Filing  
10/15/2013Trevor JonesDirectorSell2,000$90.14$180,280.007,142View SEC Filing  
9/16/2013Albert HummelDirectorSell6,200$137.81$854,422.0082,776View SEC Filing  
9/16/2013Trevor JonesDirectorSell2,000$89.78$179,560.008,142View SEC Filing  
9/4/2013George Fred WilkinsonInsiderSell16,749$138.00$2,311,362.00View SEC Filing  
9/4/2013Jack MichelsonDirectorSell6,064$139.54$846,170.56View SEC Filing  
8/29/2013David BuchenInsiderSell10,000$135.56$1,355,600.0097,373View SEC Filing  
8/26/2013Albert HummelDirectorSell40,000$134.44$5,377,600.0092,776View SEC Filing  
8/20/2013Paul BisaroCEOSell50,000$135.30$6,765,000.00469,232View SEC Filing  
8/15/2013Albert Paonessa IIIInsiderSell5,476$135.89$744,133.6433,812View SEC Filing  
8/15/2013Trevor JonesDirectorSell2,000$89.89$179,780.009,142View SEC Filing  
8/14/2013R Todd JoyceCFOSell15,000$137.98$2,069,700.0080,470View SEC Filing  
8/13/2013Albert HummelDirectorSell10,000$133.85$1,338,500.00132,776View SEC Filing  
8/12/2013Cathy KlemaDirectorSell1,667$133.03$221,761.0119,608View SEC Filing  
8/12/2013David BuchenInsiderSell17,000$133.03$2,261,510.0097,373View SEC Filing  
8/9/2013Ronald TaylorDirectorSell5,000$135.14$675,700.0027,942View SEC Filing  
8/6/2013Jeffrey EdwardsCFOSell69,200$91.17$6,308,964.0016,871View SEC Filing  
8/5/2013Charles EbertVPSell8,244$136.25$1,123,245.0019,970View SEC Filing  
8/5/2013Michel FeldmanDirectorSell10,000$136.94$1,369,400.0012,941View SEC Filing  
8/2/2013Robert StewartInsiderSell14,564$136.02$1,980,995.2873,891View SEC Filing  
7/15/2013Trevor M JonesDirectorSell2,000$91.15$182,300.00View SEC Filing  
6/17/2013Trevor M JonesDirectorSell2,000$101.25$202,500.00View SEC Filing  
5/15/2013Trevor M JonesDirectorSell2,000$103.40$206,800.00View SEC Filing  
5/9/2013Jeffrey L EdwardsCFOSell84,000$103.49$8,693,160.00View SEC Filing  
3/14/2013Charles M MayrInsiderSell1,000$91.77$91,770.00View SEC Filing  
3/12/2013Michael J FedidaDirectorSell8,000$89.00$712,000.00View SEC Filing  
11/26/2012Trevor M JonesDirectorSell2,500$91.30$228,250.00View SEC Filing  
10/5/2012David E I PyottCEOSell616,300$93.73$57,765,799.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Allergan (NYSE AGN) News Headlines

Source:
DateHeadline
Allergan Stock Down Since Q1 Earnings Report: Heres WhyAllergan Stock Down Since Q1 Earnings Report: Here's Why
www.zacks.com - May 23 at 3:36 PM
Allergan Stock Down Since Q1 Earnings Report: Here's WhyAllergan Stock Down Since Q1 Earnings Report: Here's Why
finance.yahoo.com - May 23 at 3:36 PM
Royal Caribbean, Allergan, Tyson Foods: Mad Money Lightning RoundRoyal Caribbean, Allergan, Tyson Foods: 'Mad Money' Lightning Round
www.thestreet.com - May 22 at 10:21 AM
BRIEF-Allergan Exercises Option To Acquire Compound From Aptinyx Discovery PlatformBRIEF-Allergan Exercises Option To Acquire Compound From Aptinyx Discovery Platform
www.reuters.com - May 22 at 10:21 AM
Allergan Exercises Option to Acquire Compound from Aptinyx Discovery Platform Under Ongoing Research ...Allergan Exercises Option to Acquire Compound from Aptinyx Discovery Platform Under Ongoing Research ...
www.prnewswire.com - May 22 at 10:21 AM
Insider Selling: Allergan (AGN) EVP Sells 24,425 Shares of StockInsider Selling: Allergan (AGN) EVP Sells 24,425 Shares of Stock
www.americanbankingnews.com - May 21 at 7:16 PM
Esmya Restriction In Europe Could Handcuff AllerganEsmya Restriction In Europe Could Handcuff Allergan
seekingalpha.com - May 21 at 10:31 AM
Brainstorm Health: Ebola Vaccine, Obamacare Profitability, New Migraine Drug, David Tepper and AllerganBrainstorm Health: Ebola Vaccine, Obamacare Profitability, New Migraine Drug, David Tepper and Allergan
fortune.com - May 19 at 10:22 AM
Allergan (AGN) Could See Activism from David Tepper - Wells FargoAllergan (AGN) Could See Activism from David Tepper - Wells Fargo
www.streetinsider.com - May 18 at 3:40 PM
Top Research Reports for Walmart, AT&T & Novo NordiskTop Research Reports for Walmart, AT&T & Novo Nordisk
finance.yahoo.com - May 18 at 3:40 PM
Appaloosa gets permission for activist stance with Allergan stakeAppaloosa gets permission for activist stance with Allergan stake
www.businessinsider.com - May 18 at 11:55 AM
David Tepper now has the go-ahead to go full activist on Allergan if he wants toDavid Tepper now has the go-ahead to go full activist on Allergan if he wants to
www.businessinsider.com - May 18 at 11:55 AM
Facebook Directors Face New Challenges; Allergan Talks Botox Competitors--ICYMIFacebook Directors Face New Challenges; Allergan Talks Botox Competitors--ICYMI
www.thestreet.com - May 18 at 11:55 AM
David Tepper gets US approval to take activist stance on Allergan, if he wants itDavid Tepper gets US approval to take activist stance on Allergan, if he wants it
www.cnbc.com - May 18 at 10:15 AM
Allergan (AGN) vs. Its Peers Head to Head SurveyAllergan (AGN) vs. Its Peers Head to Head Survey
www.americanbankingnews.com - May 17 at 9:18 PM
Allergans (AGN) "Buy" Rating Reiterated at Wells FargoAllergan's (AGN) "Buy" Rating Reiterated at Wells Fargo
www.americanbankingnews.com - May 17 at 6:37 PM
Charts of the Day: Walmart, Allergan, YouTubeCharts of the Day: Walmart, Allergan, YouTube
finance.yahoo.com - May 17 at 3:34 PM
Tevas Generic Restasis Could Punish AllerganTeva's Generic Restasis Could Punish Allergan
seekingalpha.com - May 17 at 10:48 AM
Allergan plc. (AGN) Ex-Dividend Date Scheduled for May 17, 2018Allergan plc. (AGN) Ex-Dividend Date Scheduled for May 17, 2018
www.nasdaq.com - May 16 at 3:40 PM
Financial Contrast: Allergan (AGN) & Its CompetitorsFinancial Contrast: Allergan (AGN) & Its Competitors
www.americanbankingnews.com - May 15 at 1:39 PM
Ex-Dividend Reminder: Duke Energy, Fortis and AllerganEx-Dividend Reminder: Duke Energy, Fortis and Allergan
www.nasdaq.com - May 15 at 11:21 AM
$3.90 Billion in Sales Expected for Allergan (AGN) This Quarter$3.90 Billion in Sales Expected for Allergan (AGN) This Quarter
www.americanbankingnews.com - May 15 at 4:57 AM
Will Mullets Bail Out Allergan?Will Mullets Bail Out Allergan?
seekingalpha.com - May 14 at 11:46 AM
Allergan (AGN) Given Consensus Rating of "Hold" by AnalystsAllergan (AGN) Given Consensus Rating of "Hold" by Analysts
www.americanbankingnews.com - May 14 at 3:58 AM
$4.03 EPS Expected for Allergan (AGN) This Quarter$4.03 EPS Expected for Allergan (AGN) This Quarter
www.americanbankingnews.com - May 13 at 1:20 AM
MARKETS: Biotech and pharma stocks could be the key to the market bull caseMARKETS: Biotech and pharma stocks could be the key to the market bull case
finance.yahoo.com - May 12 at 3:35 PM
Vraylar (Cariprazine; Gedeon Richter/Allergan/Mitsubishi Tanabe) Drug Outlook to 2026: Bipolar Disorder ...Vraylar (Cariprazine; Gedeon Richter/Allergan/Mitsubishi Tanabe) Drug Outlook to 2026: Bipolar Disorder ...
www.businesswire.com - May 11 at 3:46 PM
Allergan: Could The Break-Up Be The Solution?Allergan: Could The Break-Up Be The Solution?
seekingalpha.com - May 11 at 3:46 PM
Allergans Growth Is Really DeadAllergan's Growth Is Really Dead
seekingalpha.com - May 11 at 11:41 AM
Allergan Forecasted to Earn Q2 2018 Earnings of $4.24 Per Share (AGN)Allergan Forecasted to Earn Q2 2018 Earnings of $4.24 Per Share (AGN)
www.americanbankingnews.com - May 11 at 9:50 AM
Allergan Expected to Post Q3 2018 Earnings of $3.92 Per Share (AGN)Allergan Expected to Post Q3 2018 Earnings of $3.92 Per Share (AGN)
www.americanbankingnews.com - May 10 at 7:58 AM
How Companies Keep Most Earnings Calls So Incredibly BoringHow Companies Keep Most Earnings Calls So Incredibly Boring
finance.yahoo.com - May 9 at 3:39 PM
Morgan Stanley Turns Bearish On Ironwood Pharma, Lowers Linzess Sales EstimateMorgan Stanley Turns Bearish On Ironwood Pharma, Lowers Linzess Sales Estimate
finance.yahoo.com - May 9 at 3:39 PM
Allergan: Sell That VolatilityAllergan: Sell That Volatility
seekingalpha.com - May 8 at 3:33 PM
Raleigh pharma ushers in new CEO from AllerganRaleigh pharma ushers in new CEO from Allergan
www.bizjournals.com - May 8 at 3:33 PM
Allergan’s Valuations after Its 1Q18 EarningsAllergan’s Valuations after Its 1Q18 Earnings
finance.yahoo.com - May 7 at 3:40 PM
Allergan (AGN) Receives "Hold" Rating from Cantor FitzgeraldAllergan (AGN) Receives "Hold" Rating from Cantor Fitzgerald
www.americanbankingnews.com - May 7 at 12:57 PM
Allergan (AGN) Downgraded by ValuEngine to Strong SellAllergan (AGN) Downgraded by ValuEngine to Strong Sell
www.americanbankingnews.com - May 5 at 1:50 AM
Allergan is OversoldAllergan is Oversold
www.nasdaq.com - May 4 at 10:23 AM
BRIEF-Ironwood And Allergan Announce Settlement With Aurobindo Pharma Resolving Linzess Patent LitigationBRIEF-Ironwood And Allergan Announce Settlement With Aurobindo Pharma Resolving Linzess Patent Litigation
www.reuters.com - May 4 at 10:23 AM
Credit Suisse Group Cuts Allergan (AGN) Price Target to $213.00Credit Suisse Group Cuts Allergan (AGN) Price Target to $213.00
www.americanbankingnews.com - May 4 at 12:17 AM
Allergan (AGN) Announces Quarterly Dividend of $0.72Allergan (AGN) Announces Quarterly Dividend of $0.72
www.americanbankingnews.com - May 3 at 5:58 PM
Technical Perspectives on Generic Drugs Stocks -- Allergan, Catalyst Pharma, Flexion Therapeutics, and Supernus ...Technical Perspectives on Generic Drugs Stocks -- Allergan, Catalyst Pharma, Flexion Therapeutics, and Supernus ...
www.prnewswire.com - May 3 at 10:23 AM
Allergan: Too Much Focus On The BadAllergan: Too Much Focus On The Bad
seekingalpha.com - May 2 at 3:36 PM
Ironwood (IRWD) Incurs Loss in Q1, Announces RestructuringIronwood (IRWD) Incurs Loss in Q1, Announces Restructuring
finance.yahoo.com - May 2 at 3:36 PM
Allergan to Present Data from a Robust Mental Health Clinical Program at the American Psychiatric Association (APA ...Allergan to Present Data from a Robust Mental Health Clinical Program at the American Psychiatric Association (APA ...
www.prnewswire.com - May 2 at 10:26 AM
Allergan Abandons Psoriasis Program, But Remains Steady With Acute Migraine TreatmentAllergan Abandons Psoriasis Program, But Remains Steady With Acute Migraine Treatment
seekingalpha.com - May 2 at 10:26 AM
Allergan CEO Puts Split on Table in Urgent Review of OptionsAllergan CEO Puts Split on Table in Urgent Review of Options
www.bloomberg.com - May 2 at 10:26 AM
Cantor Fitzgerald Equities Analysts Raise Earnings Estimates for Allergan (AGN)Cantor Fitzgerald Equities Analysts Raise Earnings Estimates for Allergan (AGN)
www.americanbankingnews.com - May 2 at 9:44 AM
Q3 2018 EPS Estimates for Allergan Cut by William Blair (AGN)Q3 2018 EPS Estimates for Allergan Cut by William Blair (AGN)
www.americanbankingnews.com - May 2 at 9:26 AM

SEC Filings

Allergan (NYSE:AGN) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Allergan (NYSE:AGN) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Allergan (NYSE AGN) Stock Chart for Thursday, May, 24, 2018

Loading chart…

This page was last updated on 5/24/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.